Bank of America Corp DE Has $1.85 Million Stock Position in OrthoPediatrics Corp. (NASDAQ:KIDS)

Bank of America Corp DE decreased its holdings in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 25.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 79,595 shares of the company's stock after selling 27,572 shares during the quarter. Bank of America Corp DE owned about 0.33% of OrthoPediatrics worth $1,845,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Invesco Ltd. lifted its stake in shares of OrthoPediatrics by 3.0% in the fourth quarter. Invesco Ltd. now owns 16,363 shares of the company's stock worth $379,000 after acquiring an additional 469 shares in the last quarter. Northern Trust Corp lifted its stake in shares of OrthoPediatrics by 0.3% in the fourth quarter. Northern Trust Corp now owns 193,798 shares of the company's stock worth $4,492,000 after acquiring an additional 644 shares in the last quarter. Rhumbline Advisers raised its stake in OrthoPediatrics by 4.1% during the fourth quarter. Rhumbline Advisers now owns 26,411 shares of the company's stock valued at $612,000 after buying an additional 1,042 shares in the last quarter. Bank of New York Mellon Corp raised its stake in OrthoPediatrics by 3.8% during the fourth quarter. Bank of New York Mellon Corp now owns 57,710 shares of the company's stock valued at $1,338,000 after buying an additional 2,099 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in OrthoPediatrics by 31.1% during the fourth quarter. Wells Fargo & Company MN now owns 9,853 shares of the company's stock valued at $228,000 after buying an additional 2,338 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company's stock.

OrthoPediatrics Stock Performance

Shares of NASDAQ KIDS traded up $0.74 during mid-day trading on Thursday, hitting $20.86. The company had a trading volume of 192,451 shares, compared to its average volume of 198,387. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. The business's 50-day simple moving average is $21.82 and its 200-day simple moving average is $23.51. OrthoPediatrics Corp. has a 12 month low of $19.52 and a 12 month high of $35.99. The firm has a market cap of $506.63 million, a P/E ratio of -16.96 and a beta of 1.09.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The company had revenue of $52.41 million for the quarter, compared to analyst estimates of $51.68 million. As a group, analysts predict that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on KIDS. Lake Street Capital assumed coverage on OrthoPediatrics in a report on Monday, April 7th. They set a "buy" rating and a $37.00 target price for the company. Piper Sandler decreased their price target on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Truist Financial decreased their price target on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Stifel Nicolaus decreased their price target on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 price target on shares of OrthoPediatrics in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, OrthoPediatrics presently has an average rating of "Moderate Buy" and a consensus price target of $35.83.

Insider Activity

In other news, CEO David R. Bailey sold 6,620 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $164,573.20. Following the completion of the transaction, the chief executive officer now owns 319,155 shares of the company's stock, valued at $7,934,193.30. The trade was a 2.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the sale, the general counsel now directly owns 110,767 shares in the company, valued at $2,753,667.62. This trade represents a 4.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,732 shares of company stock valued at $589,978 in the last quarter. Company insiders own 32.70% of the company's stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.